Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GALT 
Galectin Therapeutics Inc (GALT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GALT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.78% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.47M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 0.73 - 3.90 | Updated Date 06/29/2025 |
52 Weeks Range 0.73 - 3.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -143.58% | Return on Equity (TTM) -3727.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 250248393 | Price to Sales(TTM) - |
Enterprise Value 250248393 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.04 | Shares Outstanding 63291600 | Shares Floating 44087019 |
Shares Outstanding 63291600 | Shares Floating 44087019 | ||
Percent Insiders 30.44 | Percent Institutions 15.78 |
Analyst Ratings
Rating 1 | Target Price 6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Galectin Therapeutics Inc
Company Overview
History and Background
Galectin Therapeutics Inc. was founded in 2000. It is a biotechnology company focused on developing therapies for fibrotic and inflammatory diseases. Initially focused on carbohydrate chemistry, it has shifted focus to galectin inhibitors.
Core Business Areas
- Drug Development: Developing galectin inhibitors to treat liver fibrosis, NASH (nonalcoholic steatohepatitis), and other fibrotic diseases.
Leadership and Structure
Dr. Joel Lewis serves as the Chief Executive Officer. The company has a board of directors overseeing operations and strategy.
Top Products and Market Share
Key Offerings
- Belapectin: Belapectin (GR-MD-02) is the company's lead drug candidate, a galectin-3 inhibitor. It is being developed for the treatment of NASH cirrhosis and other fibrotic diseases. There is currently no market share data as the product is in clinical development and not yet approved for commercial use. Key competitors developing similar treatments include Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on liver diseases like NASH, is experiencing significant growth due to the rising prevalence of these conditions globally. Competition is intense, with many companies pursuing similar therapeutic targets.
Positioning
Galectin Therapeutics is positioned as a company specializing in galectin-3 inhibitors, a novel approach to treating fibrosis. Their advantage lies in their focused expertise and clinical trial progress with Belapectin.
Total Addressable Market (TAM)
The NASH market is projected to reach tens of billions of dollars in the coming years. Galectin Therapeutics is positioned to capture a significant portion of this market if Belapectin receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel galectin-3 inhibitor technology
- Clinical trial progress with Belapectin
- Focused expertise in fibrosis
Weaknesses
- Limited financial resources
- Reliance on a single drug candidate
- Regulatory approval uncertainty
Opportunities
- Positive clinical trial results for Belapectin
- Partnerships with larger pharmaceutical companies
- Expansion into new fibrotic disease indications
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
- ICPT
Competitive Landscape
Galectin Therapeutics is a smaller player compared to companies like Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT). Their advantage lies in their novel approach, but they face significant competition and resource constraints.
Growth Trajectory and Initiatives
Historical Growth: Galectin Therapeutics has not yet demonstrated significant revenue growth as they are still in the clinical development phase.
Future Projections: Future growth is contingent on the successful clinical development and regulatory approval of Belapectin.
Recent Initiatives: Recent initiatives include advancing Belapectin through clinical trials for NASH cirrhosis and exploring its potential in other fibrotic diseases. They are also trying to secure partnerships.
Summary
Galectin Therapeutics is a clinical-stage biotech company focused on galectin-3 inhibitors. Its lead drug, Belapectin, is undergoing trials for NASH cirrhosis. Success hinges on positive trial results and regulatory approval. The company faces financial constraints and intense competition, presenting significant risks and opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galectin Therapeutics Inc
Exchange NASDAQ | Headquaters Norcross, GA, United States | ||
IPO Launch date 2002-09-09 | President, CEO & Director Mr. Joel Lewis CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://galectintherapeutics.com |
Full time employees 15 | Website https://galectintherapeutics.com | ||
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.